BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Degraeve AL, Moudio S, Haufroid V, Chaib Eddour D, Mourad M, Bindels LB, Elens L. Predictors of tacrolimus pharmacokinetic variability: current evidences and future perspectives. Expert Opin Drug Metab Toxicol 2020;16:769-82. [PMID: 32721175 DOI: 10.1080/17425255.2020.1803277] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Cheng F, Li Q, Wang J, Zeng F, Zhang Y. Effects and safety evaluation of Wuzhi Capsules combined with tacrolimus for the treatment of kidney transplantation recipients. J Clin Pharm Ther 2021. [PMID: 34342024 DOI: 10.1111/jcpt.13493] [Reference Citation Analysis]
2 Chavant A, Fonrose X, Gautier-Veyret E, Hilleret MN, Roustit M, Stanke-Labesque F. Variability of Tacrolimus Trough Concentration in Liver Transplant Patients: Which Role of Inflammation? Pharmaceutics 2021;13:1960. [PMID: 34834375 DOI: 10.3390/pharmaceutics13111960] [Reference Citation Analysis]
3 Cheng F, Li Q, Wang J, Hu M, Zeng F, Wang Z, Zhang Y. Genetic Polymorphisms Affecting Tacrolimus Metabolism and the Relationship to Post-Transplant Outcomes in Kidney Transplant Recipients. Pharmgenomics Pers Med 2021;14:1463-74. [PMID: 34824543 DOI: 10.2147/PGPM.S337947] [Reference Citation Analysis]
4 Chen Z, Cheng X, Zhang L, Tang L, Fang Y, Chen H, Zhang L, Shen A. The impact of IL-10 and CYP3A5 gene polymorphisms on dose-adjusted trough blood tacrolimus concentrations in early post-renal transplant recipients. Pharmacol Rep 2021. [PMID: 34089513 DOI: 10.1007/s43440-021-00288-2] [Reference Citation Analysis]
5 Bianconi G, Malissin I, Labat L, Khoudour N, Houzé P, Pallet N, Mégarbane B, Declèves X. Marked and prolonged serotonin toxicity in a tramadol-poisoned patient with a pharmacokinetic study. Clin Toxicol (Phila) 2021;:1-4. [PMID: 34287102 DOI: 10.1080/15563650.2021.1955912] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]